Navigation Links
Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
Date:9/16/2011

s.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The results of this study are expected in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:

Silence Therapeutics Singer Capital Markets Max Herrmann/Thomas Christely Shaun Dobson/Claes Spång +44(0)20-7491-6520/ +49-30-9489-2800 +44(0)20-32057500 m.herrmann@silence-therapeutics.com shaun.dobson@singercm.com t.christ
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
4. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
5. Silence Therapeutics Provides Year-end Update
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Silence Therapeutics Announces Board Changes
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... /PRNewswire-FirstCall/ --,NeurogesX, Inc. announced today the presentation of ... postherpetic neuralgia (PHN).,Misha-Miroslav Backonja, M.D., Professor of Neurology ... investigator in the,NeurogesX trial, plans to present the ... session at the Second International Congress on,Neuropathic Pain ...
... Reporting of COURAGE study results confused the public ... June 07, 2007 /PRNewswire/ -- The onslaught of,anti-stent ... shaped the,public's view that angioplasty doesn't work and ... patients have extensively,questioned their cardiologists about the benefits ...
Cached Medicine Technology:NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4To Stent or Not: Is That the Question? 2
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... ( http://www.gynecaremorcellatorlawsuit.com/ ) investigation, Bernstein Liebhard LLP has ... U.S. Food & Drug Administration’s (FDA) Obstetrics ... to explore ways to mitigate the cancer risks ... minimally invasive gynecological surgeries. According to a report ...
(Date:7/11/2014)... July 11, 2014 Utilizing the Keller ... Dr. William Koenig, has topped a record number of ... has performed over 400 successful procedures without the occurrence ... is well known across the country for his expertise ... record has long been the foundation for numerous studies ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- U.S. health officials ... were exposed to live anthrax during a safety mishap ... Control and Prevention officials have announced a moratorium on ... high-level government labs. In a report issued Friday, ... to make sure a similar incident doesn,t occur again. ...
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... working at the Swiss Institute for Experimental Cancer Research ... discovered that telomeres, the repeated DNA-protein complexes at the ... cell divides, also contain RNA. This discovery, published online ... understanding of how telomeres function, and may provide a ...
... Success of 2007 National IPF Awareness Week on ... Deadly Lung Disease, SAN JOSE, Calif., Oct. ... announced that the success of its fifth,annual National ... 60,members of Congress about the critical need to ...
... Oct. 4 The following statement was issued,today by ... and Janet,Jenner & Suggs, LLC: Out of public ... million,pound recall of potentially E. coli contaminated ground beef ... & SUGGS, LLC.,have established a registry for victims of ...
... Academy of General,Dentistry (AGD) was extremely disappointed by ... Health Insurance Program (SCHIP),reauthorization bill. The SCHIP bill ... included many important and beneficial dental,provisions intended to ... However, President Bush, who had threatened to veto ...
... provide tobacco cessation services for three more years, ... beBetter,Networks, Inc. (beBetter) has been awarded the West ... Health and Human Resources,for the Bureau for Public ... As the original vendor for the Quitline, beBetter ...
... canola,oil for common dietary fats in the U.S. ... and plant omega-3 fats,noted a modeling study published ... the American Dietetic Association (JADA). The study examined ... oils and canola oil-based,margarine for other margarines and ...
Cached Medicine News:Health News:New telomere discovery could help explain why cancer cells never stop dividing 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning 2Health News:Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning 3Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:beBetter Awarded WV Quitline Contract 2Health News:Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2
... Leica CM3050 S Cryostat Family ... excellent safety standards for practically ... The Leica CM3050 S is ... all cryosectioning research applications and ...
... 7500 is a freestanding cryostat with ... system and a radial cutting microtome. ... a wide range of specimens and ... use in high biohazard risk laboratories ...
... 560 Cryo-Star - a vision becomes ... which offer the users many benefits.,The ... cryostat with retraction that incorporates a ... and knife cooling. This facilitates applications ...
... sliding microtome with automatic fine/trim- feed ... Maintenance-free precision cross roller bearings. For ... applications in biological, botany, and materials ... x 90 mm can be accommodated. ...
Medicine Products: